Energy metabolism and metabolic sensors in stem cells: The metabostem crossroads of aging and cancer

Advances in Experimental Medicine and Biology

Volumn 824, Issue , 2014, Pages 117-140

  Menendez, Javier A ^a,b,c   Joven, Jorge ^d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Aging; Autophagy; Cancer; Metabolism; Mitophagy; Stem cells; Stemness

Indexed keywords

DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; RAPAMYCIN; RESVERATROL;

AGING; AUTOPHAGY; CANCER STEM CELL; CARCINOGENESIS; CELL AGING; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FATE; CELL FUNCTION; CELL GROWTH; CELL LINEAGE; CELL PROLIFERATION; CELL REGENERATION; CELL STRUCTURE; CELL SURVIVAL; CELL TRANSFORMATION; DNA DAMAGE; DRUG TARGETING; ENERGY METABOLISM; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC REGULATION; GLYCOLYSIS; HUMAN; LIPOGENESIS; MESENCHYMAL EPITHELIAL TRANSITION; METABOLISM; METABOSTEMNESS; MITOCHONDRION; MITOPHAGY; NEOPLASM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPROGRAMMING INDUCED SENESCENCE; SIGNAL TRANSDUCTION; SOMATIC CELL; STEM CELL; STEM CELL SELF-RENEWAL; TUMOR SUPPRESSOR GENE; ADULT STEM CELL; ANIMAL; PATHOLOGY;

ADULT STEM CELLS; AGING; ANIMALS; ENERGY METABOLISM; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84921667927     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-07320-0_10     Document Type: Chapter

References (208)

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-217.
2. Pollina EA, Brunet A. Epigenetic regulation of aging stem cells. Oncogene. 2011;30:3105-26.
3. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature. 2007;448:767-74.
4. Rando TA. Stem cells, ageing and the quest for immortality. Nature. 2006;441:1080-6.
5. Signer RA, Morrison SJ. Mechanisms that regulate stem cell aging and life span. Cell Stem Cell. 2013;12:152-65.
6. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501:328-37.
7. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem. 2013;59:168-79.
8. Shibata M, Shen MM. The roots of cancer: Stemcells and the basis for tumor heterogeneity. Bioessays. 2013;35:253-60.
9. Visvader JE. Cells of origin in cancer. Nature. 2011;469:314-22.
10. Monteiro J, Fodde R. Cancer stemness and metastasis: Therapeutic consequences and perspectives. Eur J Cancer. 2010;46:1198-203.
11. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011;108:7950-5.
12. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146:633-44.
13. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108:1397-402.
14. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the infl ammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013;110:972-7.
15. Menendez JA, Alarcón T, Corominas-Faja B, Cuyàs E, López-Bonet E, Martin AG, et al. Xenopatients 2.0: Reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle. 2014; 13(3):358-70.
16. Mantel C, Broxmeyer HE. Sirtuin 1, stem cells, aging, and stem cell aging. Curr Opin Hematol. 2008;15:326-31.
17. Cerletti M, Jang YC, Finley LW, Haigis MC, Wagers AJ. Short-term calorie restriction enhances skeletal muscle stem cell function. Cell Stem Cell. 2012;10:515-9.
18. Yilmaz ÖH, Katajisto P, Lamming DW, Gültekin Y, Bauer-Rowe KE, Sengupta S, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature. 2012;486:490-5.
19. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature. 2013;494:323-7.
20. Park JH, Glass Z, Sayed K, Michurina TV, Lazutkin A, Mineyeva O, et al. Calorie restriction alleviates the age-related decrease in neural progenitor cell division in the aging brain. Eur J Neurosci. 2013;37:1987-93.
21. Rafalski VA, Mancini E, Brunet A. Energy metabolism and energy-sensing pathways in mammalian embryonic and adult stem cell fate. J Cell Sci. 2012;125:5597-608.
22. Shyh-Chang N, Daley GQ, Cantley LC. Stem cell metabolism in tissue development and aging. Development. 2013;140:2535-47.
23. Mahmoudi S, Brunet A. Aging and reprogramming: A two-way street. Curr Opin Cell Biol. 2012;24:744-56.
24. Ochocki JD, Simon MC. Nutrient-sensing pathways and metabolic regulation in stemcells. J Cell Biol. 2013;203:23-33.
25. Zhang G, Yang P, Guo P, Miele L, Sarkar FH, Wang Z, et al. Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. Biochim Biophys Acta. 2013;1836:49-59.
26. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: A roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle. 2011;10:3658-77.
27. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F, et al. Autophagy in stemcells. Autophagy. 2013;9:830-49.
28. Pan H, Cai N, Li M, Liu GH, Izpisua Belmonte JC. Autophagic control of cell 'stemness'. EMBO Mol Med. 2013;5:327-31.
29. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras- Ferraros C, Bosch-Barrera J, Joven J, et al. Metformin: Multi-faceted protection against cancer. Oncotarget. 2011;2:896-917.
30. Menendez JA, Joven J, Cufí S, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, et al. The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells. Cell Cycle. 2013;12:1166-79.
31. Vazquez-Martin A, López-Bonet E, Cufí S, Oliveras- Ferraros C, Del Barco S, Martin-Castillo B, et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat. 2011;14:212-23.
32. Menendez JA, Joven J, Aragonès G, Barrajón- Catalán E, Beltrán-Debón R, Borrás-Linares I, et al. Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: A new family of gerosuppressant agents. Cell Cycle. 2013;12:555-78.
33. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008;7:1520-4.
34. Blagosklonny MV. Aging-suppressants: Cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle. 2009;8:1883-7.
35. Blagosklonny MV. TOR-driven aging: Speeding car without brakes. Cell Cycle. 2009;8:4055-9.
36. Blagosklonny MV. Calorie restriction: Decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle. 2010;9:683-8.
37. Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: Preliminary proposal. Cell Cycle. 2010;9:4788-94.
38. Blagosklonny MV. Molecular damage in cancer: An argument for mTOR-driven aging. Aging (Albany NY). 2011;3:1130-41.
39. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: Terminology for TOR-driven aging. Aging (Albany NY). 2012;4:159-65.
40. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY). 2012;4:899-916.
41. Blagosklonny MV. MTOR-driven quasiprogrammed aging as a disposable soma theory: Blind watchmaker vs. intelligent designer. Cell Cycle. 2013;12:1842-7.
42. Blagosklonny MV. Rapamycin extends life- and health span because it slows aging. Aging (Albany NY). 2013;5:592-8.
43. Blagosklonny MV. Aging is not programmed: Genetic pseudo-program is a shadow of developmental growth. Cell Cycle. 2013;12:3736-42.
44. Mariño G, Ugalde AP, Salvador-Montoliu N, Varela I, Quirós PM, Cadiñanos J, et al. Premature aging in mice activates a systemic metabolic response involving autophagy induction. Hum Mol Genet. 2008;17:2196-211.
45. Mariño G, López-Otín C. Autophagy and aging: New lessons from progeroid mice. Autophagy. 2008;4:807-9.
46. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392-5.
47. Cox LS, Mattison JA. Increasing longevity through caloric restriction or rapamycin feeding in mammals: Common mechanisms for common outcomes? Aging Cell. 2009;8:607-13.
48. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493:338-45.
49. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011;10:4230-6.
50. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: Chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol. 2012;181:278-93.
51. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY). 2012;4:715-22.
52. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY). 2012;4:709-14.
53. Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013;123:980-9.
54. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: A recipe for cancer growth. Genes Dev. 2009;23:537-48.
55. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 2009;324:1029-33.
56. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-74.
57. Ward PS, Thompson CB. Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.
58. Cantor JR, Sabatini DM. Cancer cell metabolism: One hallmark, many faces. Cancer Discov. 2012;2:881-98.
59. Galluzzi L, Kepp O, Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12:829-46.
60. Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, et al. Dietary restrictionresistant human tumors harboring the PIK3CAactivating mutation H1047R are sensitive to metformin. Oncotarget. 2013;4:1484-95.
61. Iglesias-Bartolome R, Gutkind SJ. Exploiting the mTOR paradox for disease prevention. Oncotarget. 2012;3:1061-3.
62. Anisimov VN. Metformin: Do we fi nally have an anti-aging drug? Cell Cycle. 2013;12:3483-9.
63. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, et al. Metformin improves health span and lifespan in mice. Nat Commun. 2013;4:2192.
64. Moiseeva O, Deschênes-Simard X, Pollak M, Ferbeyre G. Metformin, aging and cancer. Aging (Albany NY). 2013;5:330-1.
65. Anisimov VN. Metformin and rapamycin are masterkeys for understanding the relationship between cell senescent, aging and cancer. Aging (Albany NY). 2013;5:337-8.
66. Cabreiro F, Au C, Leung KY, Vergara-Irigaray N, Cochemé HM, Noori T, et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell. 2013;153:228-39.
67. Menendez JA, Joven J. One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin. Aging (Albany NY). 2012;4:894-8.
68. Corominas-Faja B, Quirantes-Piné R, Oliveras- Ferraros C, Vazquez-Martin A, Cufí S, Martin- Castillo B, et al. Metabolomic fi ngerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY). 2012;4:480-98.
69. Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC- CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell. 2012;11:23-35.
70. Berstein LM. Metformin in obesity, cancer and aging: Addressing controversies. Aging (Albany NY). 2012;4:320-9.
71. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Quirantes R, Segura-Carretero A, Micol V, et al. Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. Cell Cycle. 2012;11:1235-46.
72. Mercken EM, Carboneau BA, Krzysik-Walker SM, de Cabo R. Of mice and men: The benefi ts of caloric restriction, exercise, and mimetics. Ageing Res Rev. 2012;11:390-8.
73. Menendez JA, Cufí S, Oliveras-Ferraros C, Martin- Castillo B, Joven J, Vellon L, et al. Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY). 2011;3:1063-77.
74. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: Less is more. Aging (Albany NY). 2011;3:348-62.
75. Anisimov VN, Berstein LM, Popovich IG, Zabezhinski MA, Egormin PA, Piskunova TS, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY). 2011;3:148-57.
76. Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Egormin PA, et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY). 2010;2:945-58.
77. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010;2:760-74.
78. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7:2769-73.
79. Cufi S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, et al. Metformin-induced preferential killing of breast cancer initiating CD44 + CD24-/low cells is suffi - cient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012;3:395-8.
80. Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, et al. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle. 2012;11:974-89.
81. Vazquez-Martin A, Cufi S, Lopez-Bonet E, Corominas-Faja B, Oliveras-Ferraros C, Martin- Castillo B, et al. Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency. Sci Rep. 2012;2:964.
82. Takahashi K, Yamanaka S. Induction of pluripotent stem cell from mouse embryonic and adult fi broblast cultures by defi ned factors. Cell. 2006;126:663-76.
83. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: Facts, hypotheses, unresolved issues. Cell. 2010;143:508-25.
84. Drews K, Jozefczuk J, Prigione A, Adjaye J. Human induced pluripotent stem cells-from mechanisms to clinical applications. J Mol Med (Berl). 2012;90:735-45.
85. Ferreira LM, Mostajo-Radji MA. How induced pluripotent stem cells are redefi ning personalized medicine. Gene. 2013;520:1-6.
86. Cherry AB, Daley GQ. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med. 2013;64:277-90.
87. Liu GH, Ding Z, Izpisua Belmonte JC. iPSC technology to study human aging and aging-related disorders. Curr Opin Cell Biol. 2012;24:765-74.
88. Tiscornia G, Vivas EL, Izpisúa Belmonte JC. Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat Med. 2011;17:1570-6.
89. Rohani L, Johnson AA, Arnold A, Stolzing A. The aging signature: A hallmark of induced pluripotent stem cells? Aging Cell. 2014;13:2-7.
90. Blum B, Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res. 2008;100:133-58.
91. Knoepfl er PS. Deconstructing stem cell tumorigenicity: A roadmap to safe regenerative medicine. Stem Cells. 2009;27:1050-6.
92. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11:268-77.
93. Zhang Y, Yao L, Yu X, Ou J, Hui N, Liu S. A poor imitation of a natural process: A call to reconsider the iPSC engineering technique. Cell Cycle. 2012;11:4536-44.
94. Barrilleaux B, Knoepfl er PS. Inducing iPSCs to escape the dish. Cell Stem Cell. 2011;9:103-11.
95. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell. 2011;10:908-11.
96. Easley 4th CA, Ben-Yehudah A, Redinger CJ, Oliver SL, Varum ST, Eisinger VM, et al. mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cell Reprogram. 2010;12:263-73.
97. Wang Y, Mah N, Prigione A, Wolfrum K, Andrade- Navarro MA, Adjaye J. A transcriptional roadmap to the induction of pluripotency in somatic cells. Stem Cell Rev. 2010;6:282-96.
98. Li R, Liang J, Ni S, Zhou T, Qing X, Li H, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fi broblasts. Cell Stem Cell. 2010;7:51-63.
99. Esteban MA, Bao X, Zhuang Q, Zhou T, Qin B, Pei D. The mesenchymal-to-epithelial transition in somatic cell reprogramming. Curr Opin Genet Dev. 2012;22:423-8.
100. Liu X, Sun H, Qi J, Wang L, He S, Liu J, et al. Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol. 2013;15:829-38.
101. Lamouille S, Derynck R. Cell size and invasion in TGFbeta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007;178:437-51.
102. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011;71:3246-56.
103. Jun JI, Lau LF. The matricellular protein CCN1 induces fi broblast senescence and restricts fi brosis in cutaneous wound healing. Nat Cell Biol. 2010;12:676-85.
104. Kim KH, Chen CC, Monzon RI, Lau LF. Matricellular protein CCN1 promotes regression of liver fi brosis through induction of cellular senescence in hepatic myofi broblasts. Mol Cell Biol. 2013;33:2078-90.
105. Jun JI, Lau LF. Cellular senescence controls fi brosis in wound healing. Aging (Albany NY). 2010;2:627-31.
106. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009;23:2134-9.
107. Banito A, Gil J. Induced pluripotent stem cells and senescence: Learning the biology to improve the technology. EMBO Rep. 2010;11:353-9.
108. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460:1136-9.
109. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009;460:1145-8.
110. Liu Y, Hoya-Arias R, Nimer SD. The role of p53 in limiting somatic cell reprogramming. Cell Res. 2009;19:1227-8.
111. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009;460:1140-4.
112. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, et al. Direct cell reprogramming is a stochastic process amenable to acceleration. Nature. 2009;462:595-601.
113. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009;460:1149-53.
114. Son MJ, Son MY, Seol B, Kim MJ, Yoo CH, Han MK, et al. Nicotinamide overcomes pluripotency defi cits and reprogramming barriers. Stem Cells. 2013;31:1121-35.
115. Blagosklonny MV. Aging, stem cells, and mammalian target of rapamycin: A prospect of pharmacologic rejuvenation of aging stem cells. Rejuvenation Res. 2008;11:801-8.
116. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008;7:3355-61.
117. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle. 2009;8:1888-95.
118. Demidenko ZN, Blagosklonny MV. At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence. Cell Cycle. 2009;8:1901-4.
119. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A. 2010;107:9660-4.
120. Demidenko ZN, Blagosklonny MV. Quantifying pharmacologic suppression of cellular senescence: Prevention of cellular hypertrophy versus preservation of proliferative potential. Aging (Albany NY). 2009;1:1008-16.
121. Leontieva OV, Blagosklonny MV. CDK4/6- inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle. 2013;12:3063-9.
122. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013; 368:651-62.
123. Phadwal K, Watson AS, Simon AK. Tightrope act: Autophagy in stem cell renewal, differentiation, proliferation, and aging. Cell Mol Life Sci. 2013; 70:89-103.
124. Rubinsztein DC, Mariño G, Kroemer G. Autophagy and aging. Cell. 2011;146:682-95.
125. Gewirtz DA. Autophagy and senescence in cancer therapy. J Cell Physiol. 2014;229:6-9.
126. Wang S, Xia P, Ye B, Huang G, Liu J, Fan Z. Transient activation of autophagy via Sox2- mediated suppression of mTOR is an important early step in reprogramming to pluripotency. Cell Stem Cell. 2013;13:617-25.
127. He J, Kang L, Wu T, Zhang J, Wang H, Gao H, et al. An elaborate regulation of Mammalian target of rapamycin activity is required for somatic cell reprogramming induced by defi ned transcription factors. Stem Cells Dev. 2012;21:2630-41.
128. Prigione A, Fauler B, Lurz R, Lehrach H, Adjaye J. The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. Stem Cells. 2010;28:721-33.
129. Prigione A, Adjaye J. Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. Int J Dev Biol. 2010;54:1729-41.
130. Folmes CD, Nelson TJ, Martinez-Fernandez A, Arrell DK, Lindor JZ, Dzeja PP, et al. Somatic oxidative bioenergetics transitions into pluripotencydependent glycolysis to facilitate nuclear reprogramming. Cell Metab. 2011;14:264-71.
131. Folmes CD, Nelson TJ, Terzic A. Energy metabolism in nuclear reprogramming. Biomark Med. 2011;5:715-29.
132. Folmes CD, Nelson TJ, Dzeja PP, Terzic A. Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci. 2012;1254:82-9.
133. Panopoulos AD, Yanes O, Ruiz S, Kida YS, Diep D, Tautenhahn R, et al. The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming. Cell Res. 2012;22:168-77.
134. Folmes CD, Martinez-Fernandez A, Faustino RS, Yamada S, Perez-Terzic C, Nelson TJ, et al. Nuclear reprogramming with c-Myc potentiates glycolytic capacity of derived induced pluripotent stem cells. J Cardiovasc Transl Res. 2013;6:10-21.
135. Folmes CD, Arrell DK, Zlatkovic-Lindor J, Martinez-Fernandez A, Perez-Terzic C, Nelson TJ, et al. Metabolome and metaboproteome remodeling in nuclear reprogramming. Cell Cycle. 2013;12:2355-65.
136. Prigione A, Rohwer N, Hoffmann S, Mlody B, Drews K, Bukowiecki R, et al. HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2. Stem Cells. 2014;32:364-76.
137. Bukowiecki R, Adjaye J, Prigione A. Mitochondrial function in pluripotent stemcells and cellular reprogramming. Gerontology. 2013;60:174-82.
138. Ding WX, Yin XM. Mitophagy: Mechanisms, pathophysiological roles, and analysis. Biol Chem. 2012;393:547-64.
139. Liesa M, Shirihai OS. Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab. 2013;17:491-506.
140. Michel S, Wanet A, De Pauw A, Rommelaere G, Arnould T, Renard P. Crosstalk between mitochondrial (dys) function and mitochondrial abundance. J Cell Physiol. 2012;227:2297-310.
141. Wang K, Klionsky DJ. Mitochondria removal by autophagy. Autophagy. 2011;7:297-300.
142. Todd LR, Damin MN, Gomathinayagam R, Horn SR, Means AR, Sankar U. Growth factor erv1-like modulates Drp1 to preserve mitochondrial dynamics and function in mouse embryonic stem cells. Mol Biol Cell. 2010;21:1225-36.
143. Vazquez-Martin A, Cufi S, Corominas-Faja B, Oliveras-Ferraros C, Vellon L, Menendez JA. Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: New insight into the role of mitophagy in cell stemness. Aging (Albany NY). 2012;4:393-401.
144. Birket MJ, Orr AL, Gerencser AA, Madden DT, Vitelli C, Swistowski A, et al. A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells. J Cell Sci. 2011;124:348-58.
145. Zhang J, Khvorostov I, Hong JS, Oktay Y, Vergnes L, Nuebel E, et al. UCP2 regulates energy metabolism and differentiation potential of human pluripotent stem cells. EMBO J. 2011;30:4860-73.
146. Kim JH, Kim HY, Lee YK, Yoon YS, Xu WG, Yoon JK, et al. Involvement of mitophagy in oncogenic K-Ras-induced transformation: Overcoming a cellular energy defi cit from glucose defi ciency. Autophagy. 2011;7:1187-98.
147. Kim MJ, Woo SJ, Yoon CH, Lee JS, An S, Choi YH, et al. Involvement of autophagy in oncogenic K-Rasinduced malignant cell transformation. J Biol Chem. 2011;286:12924-32.
148. Mancias JD, Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget. 2011;2:1302-6.
149. Schieke SM, Phillips D, McCoy Jr JP, Aponte AM, Shen RF, Balaban RS, et al. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem. 2006;281:27643-52.
150. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC- 1alpha transcriptional complex. Nature. 2007;450:736-40.
151. Dai Y, Zheng K, Clark J, Swerdlow RH, Pulst SM, Sutton JP, et al. Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Hum Mol Genet. 2014;23:637-47.
152. Groenewoud MJ, Zwartkruis FJ. Rheb and mammalian target of rapamycin in mitochondrial homoeostasis. Open Biol. 2013;3:130185.
153. Li Q, Zhang T, Wang J, Zhang Z, Zhai Y, Yang GY, Sun X. Rapamycin attenuates mitochondrial dysfunction via activation of mitophagy in experimental ischemic stroke. Biochem Biophys Res Commun. 2014;444:182-8.
154. Prigione A, Lichtner B, Kuhl H, Struys EA, Wamelink M, Lehrach H, et al. Human induced pluripotent stem cells harbor homoplasmic and heteroplasmic mitochondrial DNA mutations while maintaining human embryonic stem cell-like metabolic reprogramming. Stem Cells. 2011;29:1338-48.
155. Xu X, Duan S, Yi F, Ocampo A, Liu GH, Izpisua Belmonte JC. Mitochondrial regulation in pluripotent stem cells. Cell Metab. 2013;18:325-32.
156. Vazquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, et al. The mitochondrial H(+)-ATP synthase and the lipogenic switch: New core components of metabolic reprogramming in induced pluripotent stem (iPS) cells. Cell Cycle. 2013;12:207-18.
157. O'Neill LA, Hardie DG. Metabolism of infl ammation limited by AMPK and pseudo-starvation. Nature. 2013;493:346-55.
158. Hardie DG, Ross FA, Hawley SA. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-62.
159. Hardie DG. AMP-activatedprotein kinase: An energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895-908.
160. Hardie DG. Sensing of energy and nutrients by AMP-activatedprotein kinase. Am J Clin Nutr. 2011;93:891S-6.
161. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, et al. mTOR and HIF-1alphamediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A. 2009;106:11137-42.
162. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013;17:113-24.
163. Dandapani M, Hardie DG. AMPK: Opposing the metabolic changes in both tumour cells and infl ammatory cells? Biochem Soc Trans. 2013; 41:687-93.
164. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science. 2006;312:1650-3.
165. Assaily W, Benchimol S. Differential utilization of two ATP-generating pathways is regulated by p53. Cancer Cell. 2006;10:4-6.
166. Corcoran CA, Huang Y, Sheikh MS. The regulation of energy generating metabolic pathways by p53. Cancer Biol Ther. 2006;5:1610-3.
167. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53- inducible regulator of glycolysis and apoptosis. Cell. 2006;126:107-20.
168. Zawacka-Pankau J, Grinkevich VV, Hünten S, Nikulenkov F, Gluch A, Li H, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: Targeting Warburg effect to fi ght cancer. J Biol Chem. 2011;286:41600-15.
169. Sato A, Sunayama J, Okada M, Watanabe E, Seino S, Shibuya K, et al. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK. Stem Cells Transl Med. 2012;1:811-24.
170. Cuezva JM, Sánchez-Aragó M, Sala S, Blanco- Rivero A, Ortega AD. A message emerging from development: The repression of mitochondrial beta- F1- ATPase expression in cancer. J Bioenerg Biomembr. 2007;39:259-65.
171. López-Ríos F, Sánchez-Aragó M, García-García E, Ortega AD, Berrendero JR, Pozo-Rodríguez F, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res. 2007;67:9013-7.
172. Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, Sánchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett. 2009;276:125-35.
173. Sánchez-Aragó M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis. 2010;31:567-76.
174. Sánchez-Cenizo L, Formentini L, Aldea M, Ortega AD, García-Huerta P, Sánchez-Aragó M, et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem. 2010;285:25308-13.
175. Sánchez-Aragó M, Formentini L, Martínez-Reyes I, García-Bermudez J, Santacatterina F, Sánchez- Cenizo L, et al. Expression, regulation and clinical relevance of the ATPase inhibitory factor 1 in human cancers. Oncogenesis. 2013;2:e46.
176. Sánchez-Aragó M, Formentini L, García-Bermúdez J, Cuezva JM. IF1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. Cell Cycle. 2012;11:2963-4.
177. Sánchez-Aragó M, Formentini L, Cuezva JM. Mitochondria-mediated energy adaption in cancer: The H(+)-ATP synthase-geared switch of metabolism in human tumors. Antioxid Redox Signal. 2013;19:285-98.
178. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763-77.
179. Menendez JA. Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: Molecular mechanisms and therapeutic perspectives. Biochim Biophys Acta. 1801;2010:381-91.
180. Pandey PR, Xing F, Sharma S, Watabe M, Pai SK, Iiizumi-Gairani M, et al. Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene. 2013;32:5111-22.
181. Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat. 2011;130: 387-98.
182. Cheema AK, Timofeeva O, Varghese R, Dimtchev A, Shiekh K, Shulaev V, et al. Integrated analysis of ATM mediated gene and protein expression impacting cellular metabolism. J Proteome Res. 2011;10:2651-7.
183. Ditch S, Paull TT. The ATM protein kinase and cellular redox signaling: Beyond the DNA damage response. Trends Biochem Sci. 2012;37:15-22.
184. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B, Menendez JA. Metformin activates an ataxia telangiectasia mutated (ATM)/ Chk2- regulated DNA damage-like response. Cell Cycle. 2011;10:1499-501.
185. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2012;5:355-64.
186. Jung JW, Park SB, Lee SJ, Seo MS, Trosko JE, Kang KS. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS One. 2011;6:e28068.
187. Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitorcell differentiation and causes dysplasia in epithelial tissues. Cell. 2005;121:465-77.
188. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2010;29:2153-9.
189. Hu T, Liu S, Breiter DR, Wang F, Tang Y, Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008; 68:6533-40.
190. Kim RJ, Nam JS. OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res. 2011;27:147-52.
191. Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, et al. Generation of tumorinitiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res. 2011;13:R94.
192. Shyh-Chang N, Daley GQ. Lin28: Primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 2013;12:395-406.
193. Zhou J, Ng SB, Chng WJ. LIN28/LIN28B: An emerging oncogenic driver in cancer stem cells. Int J Biochem Cell Biol. 2013;45:973-8.
194. Thornton JE, Gregory RI. How does Lin28 let-7 control development and disease? Trends Cell Biol. 2012;22:474-82.
195. Büssing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med. 2008;14:400-9.
196. Gunaratne PH. Embryonic stem cell microRNAs: Defi ning factors in induced pluripotent (iPS) and cancer (CSC) stem cells? Curr Stem Cell Res Ther. 2009;4:168-77.
197. Li MA, He L. microRNAs as novel regulators of stem cell pluripotency and somatic cell reprogramming. Bioessays. 2012;34:670-80.
198. Peter ME. Let-7 and miR-200 microRNAs: Guardians against pluripotency and cancer progression. Cell Cycle. 2009;8:843-52.
199. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S, et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 2010;70:9463-72.
200. Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, et al. Micro(mi)RNA expression profi le of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle. 2011;10:1144-51.
201. Zhu H, Shyh-Chang N, Segrè AV, Shinoda G, Shah SP, Einhorn WS, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147:81-94.
202. Shinoda G, Shyh-Chang N, Soysa TY, Zhu H, Seligson MT, Shah SP, et al. Fetal defi ciency of lin28 programs life-long aberrations in growth and glucose metabolism. Stem Cells. 2013;31:1563-73.
203. Shyh-Chang N, Zhu H, Yvanka de Soysa T, Shinoda G, Seligson MT, Tsanov KM, et al. Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell. 2013;155:778-92.
204. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci U S A. 2011;108:21075-80.
205. Qiu C, Ma Y, Wang J, Peng S, Huang Y. Lin28- mediated post-transcriptional regulation of Oct4 expression in human embryonic stem cells. Nucleic Acids Res. 2010;38:1240-8.
206. Ma W, Ma J, Xu J, Qiao C, Branscum A, Cardenas A, et al. Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. Cell Cycle. 2013;12:88-97.
207. Menendez JA, Vazquez-Martin A. Rejuvenating regeneration: Metformin activates endogenous adult stem cells. Cell Cycle. 2012;11:3521-2.
208. Wu LE, Gomes AP, Sinclair DA. Geroncogenesis: Metabolic changes during aging as a driver of tumorigenesis. Cancer Cell. 2014;25:12-9.